

CLAIMS

WHAT IS CLAIMED IS:

1. An anti-IFNAR2 antibody selected from the group consisting of antibody 1F3 produced by a hybridoma with ATCC Accession No. HP 12426 or progeny thereof, antibody 3B7 produced by a hybridoma with ATCC Accession No. HP 12427 or progeny thereof, and antibody 1D3 produced by a hybridoma with ATCC Accession No. HP 12428 or progeny thereof.
2. An anti-IFNAR2 antibody that competes for binding to IFNAR2 with the antibody of claim 1.
3. A polypeptide comprising a portion of the antibody of claim 1 or 2, wherein said portion comprises an antigen binding or a variable region of said antibody.
4. The polypeptide of claim 3, wherein said portion comprises at least one complementary determining region of said antibody.
5. The antibody of claim 2, wherein said antibody does not substantially block binding of a Type I interferon to IFNAR2.
6. The antibody of claim 5, wherein said Type I interferon is IFN α -2/1.
7. The antibody of claim 5, wherein said antibody blocks anti-viral activity of a first Type I interferon and does not block anti-viral activity of a second Type I interferon.
8. The antibody of claim 5, wherein said antibody competes for binding to IFNAR2 with antibody 1D3.

9. The antibody of claim 1 or 2, wherein said antibody is a monoclonal antibody.

10. The antibody of claim 1 or 2, wherein said antibody is a humanized antibody.

11. The antibody of claim 1 or 2, wherein said antibody is a human antibody.

12. A method of treating an immune-mediated disorder in a subject comprising administering
5 to the subject the antibody of claim 1 or 2.

13. The method of claim 12, wherein said immune-mediated disorder is selected from the
group consisting of type I diabetes, type II diabetes, systemic lupus erythematosus and
rheumatoid arthritis.

14. A composition comprising the antibody of claim 1 or 2 and an excipient.

202470-205501